|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, it is unclear whether PKM2 is involved in cyclooxygenase‑2 (COX‑2) induced apoptosis‑resistance in hepatocellular carcinoma (HCC) cells.
|
30365092 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BER significantly reduced doxorubicin (DOX)-triggered HCC repopulation in vitro and in vivo through inhibiting Caspase-3-iPLA2-COX-2 pathway.
|
31563690 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, it was confirmed that the anticancer efficacy of avicularin in HCC was dependent on the regulation of NF‑κB (p65), COX‑2 and PPAR‑γ activities.
|
31059053 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Previous studies have demonstrated that the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib shows efficacy against multiple cancers, including hepatocellular carcinoma.
|
30182439 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hypo-MSC can promote HCC progression by activating YAP and the YAP mediated lipogenesis through COX2/PGE<sub>2</sub>/EP4 axis.
|
31142342 |
2019 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The co-expression of iNOS with COX-2 may portend a particularly aggressive cancer phenotype in HCC and at the same time reveal an opportunity for pharmacological intervention.
|
31423564 |
2019 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Western blot results showed that the knockdown of PSMD4 blocked the expression of cyclooxygenase 2 (COX2), phosphorylated Sarcoma tyrosine kinase (P-SRC) and Bcl-2, but improved the levels of p53 and Bax in HCC, lung cancer, colorectal cancer, breast cancer and endometrial cancer cell lines.
|
30930224 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A novel role for ketoconazole in hepatocellular carcinoma treatment: linking PTGS2 to mitophagy machinery.
|
30653402 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the antitumor effect of RNA interference (RNAi) technology targeting COX-2 in HCC has not yet been verified.
|
31213849 |
2019 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> Expression levels of COX-2 in HCC tissues were significantly higher than those in paracancerous tissues.
|
31114336 |
2019 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Altered expression of COX-2 and TNF-α in patients with hepatocellular carcinoma.
|
30810331 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mechanistic studies revealed that MBL could interact directly with HSCs and inhibit HCC-induced HSCs activation <i>via</i> downregulating the extracellular signal-regulated kinase (ERK)/COX-2/PGE<sub>2</sub> signaling pathway.
|
30713782 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This effect was reversed by myristoylated AKT, a constitutively active form of AKT, suggesting an involvement of CDHR2-AKT-COX2 axis in the suppression of HCC growth.
|
30854092 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our study reveals that ketoconazole, a broad-spectrum antifungal agent, activates PINK1/Parkin-mediated mitophagy by downregulating COX-2, consequently resulting in the acceleration of apoptosis and thereby inhibiting the growth of HCC.
|
30287340 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The dysregulation of signaling pathways such as transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), Wnt/β-catenin (WNT), cyclooxygenase-2 (COX-2) and peroxisome proliferator-activated receptor α (PPARα) by HCV core protein is implicated in the development of HCC.
|
30643357 |
2019 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis suggests that -1195G/A, -765G/C, and +8473T/C in COX-2 may contribute significantly to HCC risk.
|
29578159 |
2018 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Cyclooxygenase‑2 (COX‑2) and β‑catenin have been attributed to the oncogenic activity of HBx in HBV‑associated HCC.
|
29693167 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma.
|
30346255 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, the findings of the present study provide evidence that the STAT3-COX-2 signaling pathway is involved in NaHS-induced cell proliferation, migration, angiogenesis and anti-apoptosis in PLC/PRF/5 cells, and suggest that the positive feedback between STAT3 and COX-2 may serve a crucial role in hepatocellular carcinoma carcinogenesis.
|
29725404 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In a further study, we showed that inhibition of YAP and COX-2 acted synergistically and more efficiently reduced the growth of HCC cells and tumor formation than either of them alone, suggesting that dual governing of YAP and COX-2 may lead to the discovery of promising therapeutic strategies for HCC patients via blocking this positive feedback loop.
|
29505957 |
2018 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
More importantly, COX-2-specific inhibitors synergistically enhanced the antitumor activity of sorafenib treatment.<b>Conclusions:</b> Our data obtained demonstrate that the COX/PGE2 axis acts as a regulator of HIF2α expression and activity to promote HCC development and reduce sorafenib sensitivity by constitutively activating the TGFα/EGFR pathway.
|
29514844 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigate long non-coding RNA (lncRNA) cox-2 in macrophage polarization and the regulatory mechanism functions in hepatocellular carcinoma (HCC).
|
29131381 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Previous researches indicated that cyclooxygenase-2 (Cox-2) might be involved in P-glycoprotein (P-gp)-mediated multidrug resistance in hepatocellular carcinoma cells.
|
28342979 |
2017 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Parameters under investigation included hepatic, non-hepatic enzymes, oxidative stress, pro-inflammatory cytokines, COX-2 and NF-κB level along with histopathological examination in HCC rats.
|
28802237 |
2017 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Using cell-based experiments, we revealed that DENV-2 infection significantly induced COX-2 expression and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) production in human hepatoma Huh-7 cells.
|
28317866 |
2017 |